Effectiveness and Safety Evaluation of Aqueduct 100-device
Primary Purpose
Cervix Uteri Dilation
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Aqueduct 100 dilation
Sponsored by
About this trial
This is an interventional treatment trial for Cervix Uteri Dilation focused on measuring cervix, cervical dilation, balloon catheter
Eligibility Criteria
Inclusion Criteria:
- Subjects, females, 18 years of age or older.
- Subjects undergoing diagnostic or operative hysteroscopies
- Subjects willing to sign informed consent form.
Exclusion Criteria:
- Subjects younger than 18 years of age
- Subjects unwilling to sign the informed consent form
- Pregnancy
Sites / Locations
- Baptist Medical Arts Surgical Center, Gynecology Department
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Aqueduct 100 dilation
Arm Description
Uterine cervix dilation through Aqueduct-100 device
Outcomes
Primary Outcome Measures
Percentage of patients in which, through 1 minute dilation with Aqueduct-100, a cervix dilation of 5mm, required for diagnostic/ operative hysteroscopy, is reached.
Efficacy evaluation of Aqueduct-100
Occurrence of Adverse Events
In vivo safety evaluation of using Aqueduct-100
Secondary Outcome Measures
Measurement of physicians'overall satisfaction with the device, through a questionnaire
Full Information
NCT ID
NCT02959567
First Posted
November 2, 2016
Last Updated
November 7, 2016
Sponsor
Aqueduct Medical Ltd
1. Study Identification
Unique Protocol Identification Number
NCT02959567
Brief Title
Effectiveness and Safety Evaluation of Aqueduct 100-device
Official Title
Effectiveness and Safety Evaluation of Aqueduct 100-device
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Unknown status
Study Start Date
November 2016 (undefined)
Primary Completion Date
October 2017 (Anticipated)
Study Completion Date
October 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Aqueduct Medical Ltd
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Evaluation of efficacy and safety of using Aqueduct -100 - Cervical Dilator Device, focusing on diagnostic or operative hysteroscopies.
Detailed Description
There are predominantly two major dilatation techniques that are employed in dilating the cervix. The first technique uses expansible dry solid material, such as laminaria (seaweed) is inserted into the cervix in its dried stiff form. In the cervix it comes into contact with body fluids that cause the laminaria to swell and enlarge the cervical cavity. The second more widespread procedure, involves the use of series of solid, rod like instruments of graduated diameter used in serial fashion by the physician (Hegar dilators). The physician first inserts a rod like dilator and replaces it with the dilator of next higher diameter. This procedure continues until adequate dilatation occurs.
The Problem is that each of the above-mentioned methods has its shortcomings: the use of the laminaria method (rarely done) requires preliminary patient visit, for insertion of the laminaria rod and is extremely slow and typically involves often as much as 10-12 hours for a significant amount of dilatation to occur.
The use of rod-like instruments (Hegar) requires general or regional anesthesia, when local anesthetics are used, the patient nevertheless frequently experiences a great amount of discomfort from the procedure. The mechanical dilatation of the cervix demands a large amount of longitudinal force that may damage or even puncture the cervix and the uterus.
Aqueduct 100 is a catheter for use in dilating various body cavities and especially the human cervix. The device will enable continuous, fast and safe dilatation of the cervix to a pre-determined diameter as a pre-procedure to intrauterine surgeries.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervix Uteri Dilation
Keywords
cervix, cervical dilation, balloon catheter
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Aqueduct 100 dilation
Arm Type
Experimental
Arm Description
Uterine cervix dilation through Aqueduct-100 device
Intervention Type
Device
Intervention Name(s)
Aqueduct 100 dilation
Primary Outcome Measure Information:
Title
Percentage of patients in which, through 1 minute dilation with Aqueduct-100, a cervix dilation of 5mm, required for diagnostic/ operative hysteroscopy, is reached.
Description
Efficacy evaluation of Aqueduct-100
Time Frame
Through study completion, an average of 11 months
Title
Occurrence of Adverse Events
Description
In vivo safety evaluation of using Aqueduct-100
Time Frame
Through study completion, an average of 11 months
Secondary Outcome Measure Information:
Title
Measurement of physicians'overall satisfaction with the device, through a questionnaire
Time Frame
Through study completion, an average of 11 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects, females, 18 years of age or older.
Subjects undergoing diagnostic or operative hysteroscopies
Subjects willing to sign informed consent form.
Exclusion Criteria:
Subjects younger than 18 years of age
Subjects unwilling to sign the informed consent form
Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Larry Spiegelman, Dr.
Phone
305 595-4070
Email
lsspmd@bellsouth.net
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Larry Spiegelman, Dr.
Organizational Affiliation
Baptist Medical Arts Surgical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Baptist Medical Arts Surgical Center, Gynecology Department
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
16143559
Citation
Mazza E, Nava A, Bauer M, Winter R, Bajka M, Holzapfel GA. Mechanical properties of the human uterine cervix: an in vivo study. Med Image Anal. 2006 Apr;10(2):125-36. doi: 10.1016/j.media.2005.06.001. Epub 2005 Sep 6.
Results Reference
background
Citation
Buhimschi, C.; Buhimschi, I.; Malinow, A.; Saade, G.; Garfield, R.; Weiner, C., The Forces of Labour. Fetal and Maternal Medicine Review 2003, 14 (4), 273-307.
Results Reference
background
PubMed Identifier
17904431
Citation
Myers KM, Paskaleva AP, House M, Socrate S. Mechanical and biochemical properties of human cervical tissue. Acta Biomater. 2008 Jan;4(1):104-16. doi: 10.1016/j.actbio.2007.04.009. Epub 2007 Sep 27.
Results Reference
background
PubMed Identifier
3391017
Citation
Kenyon NJ, Stevens JC, Stewart P, Black MM, Clifford A. A critical investigation of the measurement of the force required to dilate the human uterine cervix. Clin Phys Physiol Meas. 1988 May;9(2):155-61. doi: 10.1088/0143-0815/9/2/008.
Results Reference
background
Citation
S. Febvay, S. Socrate and M.D. House. Biomechanical modeling of cervical tissue. A quantitative investigation of cervical funneling. Proceedings of the ASME 2003 International Mechanical Engineering Congress and Exposition, Washington, D.C., November 2003.
Results Reference
background
PubMed Identifier
23088906
Citation
Arsenijevic S, Vukcevic-Globarevic G, Volarevic V, Macuzic I, Todorovic P, Tanaskovic I, Mijailovic M, Raicevic S, Jeremic B. Continuous controllable balloon dilation: a novel approach for cervix dilation. Trials. 2012 Oct 22;13:196. doi: 10.1186/1745-6215-13-196.
Results Reference
background
PubMed Identifier
6849849
Citation
Nicolaides KH, Welch CC, MacPherson MB, Johnson IR, Filshie GM. Lamicel: a new technique for cervical dilatation before first trimester abortion. Br J Obstet Gynaecol. 1983 May;90(5):475-9. doi: 10.1111/j.1471-0528.1983.tb08947.x.
Results Reference
background
Learn more about this trial
Effectiveness and Safety Evaluation of Aqueduct 100-device
We'll reach out to this number within 24 hrs